NCT02684162View on ClinicalTrials.gov

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

June 22, 2016

Primary Completion Date

October 8, 2024

Study Completion Date

October 8, 2024

Conditions
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic Syndrome
Interventions
BIOLOGICAL

Donor Lymphocytes

Given IV

DRUG

Guadecitabine

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02684162 - Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant | Biotech Hunter | Biotech Hunter